Crescent Grove Advisors’s Immunic IMUX Stock Holding History

Crescent Grove Advisors’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,000	Closed	-$11.1K	–	315
2026 Q1	$11.1K	Hold	1,000	–	–	﹤0.01%	302
2025 Q4	$5.34K	Hold	1,000	–	–	﹤0.01%	296
2025 Q3	$8.82K	Hold	1,000	–	–	﹤0.01%	292
2025 Q2	$6.97K	Hold	1,000	–	–	﹤0.01%	284
2025 Q1	$10.9K	Buy	+1,000	New	+$10.8K	﹤0.01%	259

Other funds holding IMUX

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Crescent Grove Advisors's IMUX Position: Q2 2026 in Review

Crescent Grove Advisors sold out of Immunic (IMUX) in Q2 2026, closing a stake of 1,000 shares — an estimated $11.1K sold.

Crescent Grove Advisors first reported a position in IMUX in Q1 2025 and held it in 5 quarters. The position peaked at $11.1K in Q1 2026. 55 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

Crescent Grove Advisors reported no remaining Immunic position as of Q2 2026 after selling out during the quarter.
Crescent Grove Advisors sold 1,000 Immunic shares in Q2 2026, an estimated $11.1K.
Crescent Grove Advisors first reported a position in Immunic in Q1 2025 and held it in 5 quarters.
Crescent Grove Advisors's Immunic position peaked at $11.1K in Q1 2026.
55 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on Crescent Grove Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.